Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine

Scott T. Tagawa, MD, FASCO, FACP, MS, discusses the addition of lutetium 177Lu-rosopatamab tetraxetan to SOC in mCRPC.

Scott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.

Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.

Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.

Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.

The significance of using broad genomic profiling tests to help detect promising biomarkers in metastatic urothelial cancer.

An overview of the types of health care professionals who may help manage patients with metastatic urothelial cancer throughout their disease course.

A discussion on molecular testing in the community and recommendations that can address barriers.

The impact of the COVID-19 pandemic on rates of molecular testing used by community oncologists who care for patients with urothelial cancer.

A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.

Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

Treatment Advances in mCSPC

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

An interpretation of the OSPREY study of 18F-DCFPyL injection in patients with high-risk prostate cancer and implications of its use.

Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.

A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.